188 related articles for article (PubMed ID: 33151394)
21. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
22. The value of
Garcia JR; Cozar M; Baquero M; Fernández Barrionuevo JM; Jaramillo A; Rubio J; Maida G; Soler M; Riera E
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):85-90. PubMed ID: 27503425
[TBL] [Abstract][Full Text] [Related]
23. In silico study of pseudoprogression in glioblastoma: collaboration of radiologists and radiation oncologists in the estimation of extent of high dose RT region.
Belanova R; Sprlakova-Pukova A; Standara M; Janu E; Koukalova R; Kristek J; Burkon P; Kolouskova I; Prochazka T; Pospisil P; Chakravarti A; Slampa P; Slaby O; Kazda T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):307-313. PubMed ID: 31544900
[TBL] [Abstract][Full Text] [Related]
24. Advances in neuro-oncology imaging.
Langen KJ; Galldiks N; Hattingen E; Shah NJ
Nat Rev Neurol; 2017 May; 13(5):279-289. PubMed ID: 28387340
[TBL] [Abstract][Full Text] [Related]
25. High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Achari R; Arunsingh M; Badgami RK; Saha A; Chatterjee S; Shrimali RK; Mallick I; Arun B
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):335-343. PubMed ID: 28188088
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
27. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
[TBL] [Abstract][Full Text] [Related]
28. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Rapp M; Sadat H; Slotty PJ; Steiger HJ; Budach W; Sabel M
J Neurol Surg A Cent Eur Neurosurg; 2015 Jul; 76(4):298-302. PubMed ID: 25915500
[TBL] [Abstract][Full Text] [Related]
30. Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.
Gonçalves FG; Chawla S; Mohan S
J Magn Reson Imaging; 2020 Oct; 52(4):978-997. PubMed ID: 32190946
[TBL] [Abstract][Full Text] [Related]
31. Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.
Kerkhof M; Hagenbeek RE; van der Kallen BF; Lycklama À Nijeholt GJ; Dirven L; Taphoorn MJ; Vos MJ
Eur J Neurol; 2016 Oct; 23(10):1528-33. PubMed ID: 27424939
[TBL] [Abstract][Full Text] [Related]
32. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
34. Overcoming challenges of translating deep-learning models for glioblastoma: the ZGBM consortium.
Shuaib H; Barker GJ; Sasieni P; De Vita E; Chelliah A; Andrei R; Ashkan K; Beaumont E; Brazil L; Rowland-Hill C; Lau YH; Luis A; Powell J; Swampillai A; Tenant S; Thust SC; Wastling S; Young T; Booth TC;
Br J Radiol; 2023 Jan; 96(1141):20220206. PubMed ID: 35616700
[TBL] [Abstract][Full Text] [Related]
35. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
[TBL] [Abstract][Full Text] [Related]
36. Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Wee CW; Kim E; Kim TM; Park CK; Kim JW; Choi SH; Yoo RE; Lee ST; Kim IH
J Neurooncol; 2017 Aug; 134(1):169-175. PubMed ID: 28547592
[TBL] [Abstract][Full Text] [Related]
37. Amide proton transfer imaging of glioblastoma, neuroblastoma, and breast cancer cells on a 11.7 T magnetic resonance imaging system.
Tanoue M; Saito S; Takahashi Y; Araki R; Hashido T; Kioka H; Sakata Y; Yoshioka Y
Magn Reson Imaging; 2019 Oct; 62():181-190. PubMed ID: 31302222
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma survival is better analyzed on preradiotherapy MRI than on postoperative MRI residual volumes: A retrospective observational study.
De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Charni S; Cohen-Jonathan-Moyal E; Roux FE
Clin Neurol Neurosurg; 2020 Sep; 196():105972. PubMed ID: 32512407
[TBL] [Abstract][Full Text] [Related]
39. Early imaging marker of progressing glioblastoma: a window of opportunity.
Gatson NTN; Bross SP; Odia Y; Mongelluzzo GJ; Hu Y; Lockard L; Manikowski JJ; Mahadevan A; Kazmi SAJ; Lacroix M; Conger AR; Vadakara J; Nayak L; Chi TL; Mehta MP; Puduvalli VK
J Neurooncol; 2020 Jul; 148(3):629-640. PubMed ID: 32602020
[TBL] [Abstract][Full Text] [Related]
40. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
